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PolymorphismA B S T R A C T
MicroRNAs (miRNAs) play an important role in regulating gene expression at the post-
transcriptional level and are involved in numerous physiological processes. Accumulating
evidence suggests that single-nucleotide polymorphisms (SNPs) in human miRNA genes may
affect miRNA biogenesis pathway and influence the susceptibility to several diseases such as
cancer. The present study aimed to evaluate the impact of miR-499 rs3746444, miR-196a2
rs11614913, miR-149 rs2292832, and miR-146a rs2910164 polymorphisms on prostate cancer
(PCa) risk in a sample of Iranian population. This case-control study was done on 169 patients
with pathologically confirmed PCa and 182 benign prostatic hyperplasia (BPH). The genotyp-
ing assays were done using T-ARMS-PCR or PCR-RFLP methods. The findings indicated that
CC genotype of miR-499 rs3746444 polymorphism increased the risk of PCa (OR= 1.76, 95%
CI = 1.12–2.79, P= 0.019) compared to TT genotype. No statistically significant association
was found between miR-196a2 rs11614913, miR-149 rs2292832, and miR-146a rs2910164
polymorphisms and PCa risk. In summary, the findings indicated that miR-499 rs3746444
polymorphism increased the risk of PCa in an Iranian population. Further studies with larger
sample sizes and different ethnicities are necessary to verify the findings of the present study.
 2016 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
Prostate cancer (PCa) is the most malignant tumor among men
in the United States [1]. The lowest incidence rate of PCa is in
the Asian population [2,3]. In Iran, the incidence rate of PCa is
approximately 9.6 per 100,000 [4,5] which is comparable to
Asia–Pacific region (9.9 per 100,000), but considerably lower
than the world (32.8 per 100,000) [6].However, the exact mech-
anisms underlying the development and progression of PCa
remain generally unknown. It has been proposed that both
genetic and environmental factors contribute to the develop-
ment and progression of PCa [7–9]. Genetic factors have been
estimated to account for over 40% of PCa risk. Single nucleo-
tide polymorphism (SNP) is the most common type of genetic
variation in human genome and has been shown to be associ-
ated with PCa risk [10–12]. Genomewide association studies
(GWAS) showed that more than 100 single nucleotide
polymorphisms (SNPs) involved in prostate cancer (PCa) risk.
However, the molecular mechanisms are unclear for most of
these SNPs [13].
MicroRNAs (miRNAs) are a class of small single-stranded
noncoding RNAs usually composed of about 17–25 nucleo-
tides. They widely exist in human cells and regulate gene
expression at the posttranscriptional level via either transla-
tional repression or mRNA degradation through binding to
the 30-untranslated region (30-UTR) of target mRNAs
[14–16]. miRNAs play an important regulating role in many
biological processes, including cell proliferation, differentia-
tion, and apoptosis, and also function as tumor suppressors
and oncogenes [17–20].
SNPs residing within the miRNA genes could potentially
alter various biological processes by influencing the miRNA
biogenesis and altering target selection [21]. SNPs and muta-
tions in miRNAs or miRNA target sites may affect the matu-
ration process or target selection, respectively [22–25]. Several
studies investigated the impact of mIR polymorphisms and
risk of various cancers. In a meta-analysis performed by Fan
et al. [26] revealed no significant association between miR-
499 rs3746444 polymorphism and cancer risk. But in subgroupanalysis by cancer type, this variant was associated with an
increased risk of BC. The findings of a meta-analysis did not
support an association between mIR-196a2 rs11614913,
mIR-146a rs2910164, and mIR-423 rs6505162 polymorphism
and esophageal cancer risk [27]. The findings of a meta-
analysis revealed that miR-146a rs2910164 polymorphism is
associated with increased risk for cervical and skin squamous
cell carcinoma (SCC), while this variant decreased the risk of
nasopharyngeal and oral SCC [28].
The miR-149 rs2292832 variant may decrease the risk of
digestive cancer [29]. It has been reported that miR-146a
rs2910164 polymorphism marginally decreased the risk of
gastric cancer [30]. The rs3746444 variant of miR-499 has been
reported to be associated with susceptibility to cancer [28].
There is little and inconsistent data regarding the impact of
miRNA gene polymorphisms on risk/protection of PCa
[31,32]. To the best of our knowledge, there is no report
regarding the impact of miRs variants on PCa risk in Iranian
population. Hence, the current study was aimed to find out the
possible association between miR-499 rs3746444, miR-196a2
rs11614913, miR-146a rs2910164 and mir-149 rs2292832
variants polymorphisms and PCa in a sample of Iranian
population.Patients and methods
Patients
This case-control study was done on 169 unrelated men with
histopathologically confirmed adenocarcinoma of prostate
and 182 ages matched unrelated men with benign prostatic
hyperplasia (BPH) with no history of any cancer. The study
design and recruitment procedures were described previously
[33]. The demographic and clinicopathological characteristics
are shown in Table 1. Briefly, all subjects were registered from
Department of Urology, Shahid Labbafinejad Medical Center,
Shahid Beheshti University of Medical Sciences, Tehran,
Iran. The project was approved by local Ethics Committee of
Table 1 Demographic and clinicopathological characteristics of prostate cancer (PCa) and control subjects.
Factors Prostate Cancer Control
Age, Mean ± SD (Years) 61.36 ± 6.61 62.51 ± 7.67
Post-void residual, mean ± SD (mL) 27.2 ± 25.2 –
PSA at diagnosis mean ± SD (ng/mL) 14.9 ± 14.3 –
Gealson score
66 57 (33.7) –
7 73 (43.2) –
>7 39 (23.1) –
Stage
PT1 8 (4.7) –
PT2a 27 (16.0) –
PT2b 11 (6.5)
PT2c 76 (45.0) –
PT3a 13 (7.7) –
Perineural invasion
Yes 106 (62.7) –
No 63 (37.3) –
Impotency
Yes 26 (15.74) –





Yes 8 (4.7) 4 (2.2)
No 161 (95.3) 178 (97.8)
Any history of smoking
Yes 27 (16.0) 6 (3.3)
No 142 (84.0) 176 (96.7)
Alcohol drinking
Yes 7 (4.1) 0 (0.0)
No 162 (95.9) 182 (0.0)
Hypertension
Yes 23 (13.6) 5 (2.7)
No 146 (86.4) 177 (97.3)
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informed consent was obtained from all cases and controls.
Blood samples were collected in EDTA-containing tubes and
genomic DNA was extracted using salting out method as
described previously [34].
Genotyping
The primers used for detection of miRs polymorphisms are
shown in Table 2. Genotyping of miR-146a rs2910164, and
miR-196a2 rs11614913 was performed using T-ARMS-PCR
assay as described previously [35,36]. Genotyping of miR-499
rs3746444 [37] and miR-149 rs2292832 was performed by
PCR-RFLP method. PCR was done using commercially avail-
able Prime Taq premix (Genetbio, South Korea) according to
the manufacturer’s recommended protocol. In each 0.20 mL
reaction PCR reaction tube, 1 lL of genomic DNA (100 ng/mL),
1 lL of each primers (10 lM), 10 lL of 2X Prime Taq Premix
and appropriate amount of ddH2O were added. The PCR
conditions were set as follows: 5 min at 95 C, followed by
30 cycles of 30 s at 95 C, 30 s at 62 C for rs2910164, 63 C
for rs11614913, 64 C for rs3746444, 66 C for rs2292832,and 72 C for 30 s with a final extension step of 72 C for
10 min. For detection of rs2292832 and rs3746444 variants,
10 lL of PCR product digested by restriction enzymes
(Table 2). The PCR products were electrophoresed on agarose
gel containing 0.5 lg/mL ethidium bromide and visualized on
a UV transilluminator.
Statistical analysis
Statistical analysis was done using statistical package SPSS 20
software. Data were analyzed by independent sample t-test
and v2 test. Association between polymorphisms and PCa
was calculated by computing the odds ratio (OR) and 95%
confidence intervals (95% CI) from logistic regression
analyses. The statistical level of significance was defined as
P-value less than 0.05.Results
The study group consists of 169 Pca patients with an average
age of 61.36 ± 6.61 years and 182 benign prostatic hyperplasia
Table 2 The primers used for miR polymorphisms genotyping.
Polymorphism Sequence (50 P 30) Restriction enzyme Product size (bp)




FI (C allele): ATGGGTTGTGTCAGTGTCAGACGTC
RI (G allele): GATATCCCAGCTGAAGAACTGAATTTGAC




FI (T allele): AGTTTTGAACTCGGCAACAAGAAACGGT
RI (C allele): GACGAAAACCGACTGATGTAACTCCGG
miR-149 rs2292832 C > T F: CTCTGGCTCCGTGTCTTCACTC PvuII C allele: 225
T allele: 154, 71R: CCTGCAGGTTCTGAGGGGC
miR-499 rs3746444 T > C F: CAAAGTCTTCACTTCCCTGCCA BclI C allele: 146
T allele: 122, 24R: GATGTTTAACTCCTCTCCACGTGATC
494 M. Hashemi et al.(BPH) with a mean age of 62.51 ± 7.67 years. No significant
difference was found between the groups concerning age using
independent sample t-test (P= 0.135).
The genotypes and allele frequencies of miR polymor-
phisms in PCa and control subjects are shown in Table 3.
The results proposed that that TC genotype of miR-499
rs3746444 polymorphism increased the risk of PCa
(OR= 1.76, 95% CI = 1.12–2.79, P= 0.019) compared to
TT genotype, while the minor allele frequency (C allele) of
rs3746444 was not associated with PCa.
As shown in Table 3, the miR-196a2 rs11614913, miR-146a
rs2910164 and Mir-149 rs2292832 variants were not associated
with PCa in any inheritance models tested (co-dominant, dom-
inant and recessive). Regarding miR-149 rs2292832 C > T the
result is not strong enough to attain a P-value < 0.05 but there
is a tendency toward that.
As shown in Table 4, miR-146a rs2910164 variant was
significantly associated with stage of disease [contingency
coefficient (CC) = 0.333, P= 0.021]. The findings showed
no significant association between miR-149 rs2292832, miR-
196a2 rs11614913 and miR-499 rs3746444 polymorphism and
clinicopathological characteristics of the PCa patients
(Table 4).
Discussion
In the current study we examined the impact of miR-146a
rs2910164, miR-149 rs2292832, miR-196a2 rs11614913 and
miR-499 rs3746444 polymorphisms on PCa risk in a sample
of Iranian population. We found that miR-499 rs3746444 vari-
ant significantly increased the risk of PCa in the population
studied. The results did not support an association between
miR-146a rs2910164, mir-149 rs2292832 and miR-196a2
rs11614913 polymorphism and PCa risk. Till now, 3 studies
investigated the impact of miRNA polymorphisms on PCa
susceptibility. Findings of George et al. [38] study showed that
heterozygous genotype in miR196a2 and miR-499, heterozy-
gotes confers the increased risk of developing PCa in North
Indian population.
Nikolic et al. [31] have found no statistically significant
association between miR-499 rs3746444 and miR-196a2
rs11614913 variant and PCa risk in Serbian population. Their
findings proposed that rs3746444 variant is associated with
PCa aggressiveness so that the rs3746444 minor allele G
confers the decreased risk of PCa progression.Xu et al. [32] found the subjects carrying miR-146a
rs2910164 CC had a 0.65-fold reduced risk (95% CI = 0.43–
0.99) than those carrying GG/GC genotypes (P= 0.03), and
the C allele displayed a lower prevalence of PCa compared
with the G allele (OR = 0.73, 95% CI = 0.57–0.94,
P= 0.01).
Wang et al. [39] performed a meta-analysis and found that
miR-146a rs2910164 polymorphism increased the risk of can-
cer risk in dominant model when all studies were pooled into
the meta-analysis. Stratified analysis revealed that significant
association between rs2910164 variant and cancer susceptibil-
ity was found in Asians but not in Caucasian populations. In
the subgroup analysis by cancer types, no significantly
increased risk of breast, gastric, prostate or bladder cancer
was found in any of the genetic models. While, another
meta-analysis indicated that miR-146a rs2910164 C allele
decreased PCa risk among Chinese population [40,41].
It has been shown that the expression level of hsa-miR-155,
hsa-miR-141 and hsa-miR-21 significantly elevated in PCa
samples and negatively correlated with that of mismatch repair
genes [42].
Previously we have investigated the impact of hsa-mir-146a
rs2910164, has-miR-499 rs3746444 and Hsa-miRNA-196a2
(rs11614913 C > T and rs185070757 T > G) and risk of
breast cancer. The results showed an association between
miR-499 rs3746444 variant and risk of BC [43].
The miR-499 gene was mapped to 20q11.22. It lies within
the 20th intron of the beta-myosin heavy chain 7B (Myh7b)
gene. The miR-499 variant may influence the individual sus-
ceptibility to cancer risk by affecting MYH7B gene function
as well functions of miR-499 [44,45]. It has been shown that
MDM4 oncogene contributes to cancer susceptibility and pro-
gression through its capability to negatively regulate tumor
suppressor genes [46]. The rs4245739 A > C variant located
in the 30-untranslated region (UTR) has been reported to cre-
ate a target site for hsa-miR-191, resulting in decreased
MDM4 mRNA levels [47]. Computational calculations
revealed that this variant is located within a predicted binding
site for miR-191-5p, miR-887 and miR-3669. Thus theMDM4
rs4245739 A allele may be associated with increased risk of
PCa [47]. MiR-143 is one major tumor suppressor miRNA.
A functional rs4705342 T > C variant in miR-143 promoter
has shown to be associated with PCa risk [48]. Subjects with
TC/CC genotypes had significantly decreased risk of PCa com-
pared with those with TT genotype. It has been proposed that
Table 3 Genotypic and allelic frequencies of miR499 rs3746444, miR-196a2 rs11614913, miR-146a rs2910164 and miR-149 rs2292832
variants polymorphisms in prostate cancer (PCa) and control subjects.




OR (95% CI) P-value
miR-499 rs3746444 T > C
Codominant
TT 62 (37.6) 85 (46.7) 1.00 –
TC 82 (48.5) 64 (35.2) 1.76 (1.12–2.79) 0.019
CC 25 (14.8) 33 (18.1) 1.04 (0.56–1.92) 0.897
Dominant
TT 62 (37.6) 85 (46.7) 1.00 –
TC+ CC 107 (62.4) 97 (53.3) 1.51 (0.99–2.32) 0.066
Recessive
TT+ TC 144 (85.2) 149 (81.9) 1.00 –
CC 25 (14.8) 33 (18.1) 0.78 (0.44–1.38) 0.472
Allele
T 206 (60.9) 234 (64.3) 1.00 –
C 132 (39.1) 130 (35.7) 1.02 (0.85–1.57) 0.390
miR-196a2 rs11614913 C > T
Codominant
CC 64 (37.9) 77 (42.3) 1.00 –
CT 88 (52.1) 93 (51.1) 1.14 (0.73–1.77) 0.576
TT 17 (10.0) 12 (6.6) 1.70 (0.76–3.82) 0.224
Dominant
CC 64 (37.9) 77 (42.3) 1.00 –
CT+ TT 105 (62.1) 105 (57.7) 1.20 (0.78–1.85) 0.446
Recessive
CC+ CT 152 (90.0) 170 (93.4) 1.00 –
TT 17 (10.0) 12 (6.6) 1.58 (0.73–3.43) 0.251
Allele
C 216 (63.9) 247 (67.9) 1.00 –
T 122 (36.1) 117 (32.1) 1.19 (0.87–1.63) 0.300
miR-149 rs2292832 C > T
Codominant
CC 77 (45.6) 101 (55.5) 1.00 –
CT 68 (40.2) 57 (31.3) 1.57 (0.99–2.480) 0.062
TT 24 (14.2) 24 (13.2) 1.31 (0.69–2.48) 0.418
Dominant
CC 77 (45.6) 101 (55.5) 1.00 –
CT+ TT 92 (54.4) 81 (44.5) 1.49 (0.98–2.27) 0.069
Recessive
CC+ CT 145 (85.8) 168 (86.8) 1.00 –
TT 24 (14.2) 24 (13.2) 1.16 (0.63–2.13) 0.645
Allele
C 222 (65.7) 258 (70.9) 1.00 –
T 116 (34.3) 106 (29.1) 1.27 (0.92–1.75) 0.144
miR-146a rs2910164 G > C
Codominant
GG 25 (14.8) 24 (13.2) 1.00 –
GC 131 (77.5) 147 (80.8) 0.86 (0.47–1.57) 0.644
CC 13 (7.7) 11 (6.0) 1.14 (0.43–3.02) 0.917
Dominant
GG 25 (14.8) 24 (13.2) 1.00 –
GC+ CC 144 (85.2) 158 (86.8) 0.87 (0.48–1.60) 0.758
Recessive
GG+GC 156 (92.3) 171 (94.0) 1.00 –
CC 13 (7.7) 11 (6.0) 1.29 (0.56–2.98) 0.673
Allele
G 181 (53.6) 195 (53.6) 1.00 –
C 157 (46.4) 169 (46.4) 1.00 (0.74–1.35) 0.974
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Table 4 Association of miR polymorphisms with clinicopathologic parameters in prostate cancer (PCa) patients.
Factors miR-499 rs3746444 P miR-196a2 rs11614913 P miR-149 rs2292832 P miR-146a rs2910164 P
TT TC CC CC CT TT CC CT TT GG GC CC
Age at diagnosis Y, n 0.333 0.797 0.536 0.902
665 47 59 15 46 64 11 56 46 19 18 93 10
>65 15 23 10 18 24 6 21 22 5 7 38 3
Stage 0.144 0.532 0.761 0.021
pT1 1 5 2 3 5 0 5 2 1 2 3 3
pT2a 8 16 3 11 15 1 12 13 2 2 25 0
pT2b 6 5 0 3 7 1 6 3 2 2 8 1
pT2c 27 33 16 32 36 8 37 28 11 12 59 5
pT3a 3 7 3 7 5 1 6 6 1 4 7 2
pT3b 17 16 1 8 20 6 11 16 7 3 29 2
PSA at diagnosis (ng/ml), n 0.094 0.061 0.722 0.545
64 1 0 0 0 0 1 1 0 0 0 1 0
4–10 24 43 17 32 44 8 41 32 11 14 61 9
>10 37 39 8 32 44 8 35 36 13 11 69 4
Gleason score, n 0.334 0.238 0.998 0.465
66 18 26 13 26 28 3 26 23 8 8 42 7
7 28 37 8 25 41 7 34 29 10 12 56 5
>7 16 19 4 13 19 7 17 16 6 5 33 1
Perineural invasion, n 0.728 0.781 0.431 0.122
Positive 41 49 16 38 57 11 52 41 13 18 83 5
Negative 21 33 9 26 31 6 25 27 11 7 48 8
Surgical margin, n 0.330 0.215 0.715 0.731
Positive 28 32 7 20 39 8 30 29 8 11 52 4
Negative 34 50 18 44 49 9 47 39 16 14 79 9
The bold indicate statistically significant.
496 M. Hashemi et al.genetic variants in miRs and miR target sites predict biochem-
ical recurrence after radical prostatectomy in localized prostate
cancer [25].
A meta-analysis performed by Ma et al. [49], investigated
the association between miR-146a rs2910164, miR-196a2
rs11614913, miR-499 rs3746444, miR-149 rs2292832, and
miR-27a rs895919 and the risk of cancer development. They
found no significant association between rs2910164 and cancer
risk in the overall group. However, in stratified analysis, they
found that either the rs2910164 C allele or the CC genotype
was protective against bladder cancer, prostate cancer, cervical
cancer, and colorectal cancer, while it was a risk factor for
papillary thyroid carcinoma and squamous cell carcinoma of
the head and neck (SCCHN). In addition, rs11614913 was
found to be significantly associated with decreased cancer risk,
in particular, for bladder cancer, gastric cancer, and SCCHN.
For miR-499, a significant association was found between the
rs3746444 polymorphism and cancer risk in pooled analysis.
It has been reported that genetic variants in the miR
machinery gene GEMIN4 are associated with risk of PCa in
Chinese Han population [50]. It has been shown that
rs1434536 variant in the 30UTR of bone morphogenetic
protein membrane receptor type IB (BMPR1B) gene affects
the binding ability of miR-125b to BMPR1B mRNA and
contributes to the genetic susceptibility to localized PCa as well
as patients aged >70 years [51]. Prostate tumor invasion and
hormone refractoriness may be caused by aberrant expression
of miR-146a and miR-146b-5p [52].
The limitations of the present study are the following: (i)
relatively small sample sizes, so replication with larger sampleis needed. (ii) We did not determine gene-environment
interactions. It has been proposed that both genetic and
environmental factors may contribute to prostate cancer
susceptibility.
Conclusions
In conclusion, the findings proposed that miR-499 rs3746444
polymorphism increased the risk of PCa. The results did not
support an association between genetic variant of miR-
196a2, miR-149, and miR-146a and the risk of developing
PCa. Larger sample sizes with diverse ethnicities are needed
to confirm the findings.
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